Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen £14 million worth of investment on its portal to date. Brickowner will use the investment towards technology up-gradation, hire strategic personnel to expand marketing, and increase its marketing spend.
days to go:
Expired
investment:
£132,528
Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.
days to go:
Expired
investment:
£558,845
Brickowner aims to become the leading service provider for property developers and asset managers, ensuring benefits for both parties. The company asserts that it undertakes background checks of investors on its portal for the benefit of asset managers. It also ensures that investors can easily navigate its portal and find deals that suit their financial appetite. Brickowner successfully exited five investment rounds despite two investments happening in the wake of COVID-19. The platform has over 3,000 investors registered with over 700 active investors. It has overseen over £15 million worth of investments on its portal till date. Brickowner will use the investment towards technology up-gradation, develop its B2B capacity, and increase marketing initiatives to support company growth
days to go:
Expired
investment:
£290,362
Mr Lee’s Pure Foods is an innovative food/tech company creating award-winning premium healthy noodles-in-a-cup and will be launching its new instant Congee Asian rice porridge. All products are certified low sugar, gluten-free, low on calories, Vegan options and 100% recyclable and compostable packaging. The global instant noodle market is expected to reach $57.5 billion by 2024 which the brand aims to capitalise on and establish itself in as the market leader. Mr Lee's has won 50+ global awards and nominations including Grocer Gold Exporter of the Year, Great British Entrepreneur winner, and The Sunday Times Maserati 100 winner. Noted publisher Penguin Random House has published Mr Lee’s 100 Noodle Recipe cookbook which has been met with critical acclaim worldwide. With the investment, the company will invest 25% of it in marketing initiatives and entering into the US market, 10% in product development, 20% in working capital for food production during scale-up, 5% in upgrading its Hot Noodle Kiosk and vending machine facilities, and 40% in global group operating and personnel costs runway for commercial functions and scale-up activities within Australia, the UK, and the USA.
days to go:
Expired
investment:
£1,835,892
Coconuts Organic is a company that produces plant-based ice creams. Coconuts Organic asserts that it is one of only two mainstream organic plant-based ice cream brands in the UK. The company aims to tap into the fast-growing global trend of healthier eating and sustainable food. Coconuts Organic has won seven Great Taste Awards and became the fastest-growing 'Wellness Ice Cream' brand in the UK according to a May 2020 Nielsen report. Its products are stocked in major retail chains like M&S and Ocado. The company will use the investment to grow its sales and marketing team, increase its eCommerce business, scale its operations, and invest in marketing activity that will create consumer demand.
days to go:
Expired
investment:
£327,979
ByRuby is a food delivery company. It sources produce from local ethical suppliers, prepares meals in small batches using the raw produce, freezes the meal to preserve the taste, and delivers it nationwide. ByRuby argues that the UK ready meal sales market is worth £12 billion in 2020. The company witnessed sales up to 200% online in March 2020. ByRuby asserts that it uses only British free-range or organic meat & sustainably sourced fish from British waters. The company won the 2018 Women's Health Food Award. Its products are stocked in 26 retail stores. ByRuby has been mentioned by publications such as Daily Mail, Daily Telegraph, and Metro. It will use 50% of the investment for marketing, 26% to grow its kitchen team, 17% to upgrade its kitchen and 7% for new product development.
days to go:
Expired
investment:
£288,243
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
